BACKGROUND: Cerebrovascular disease (CVD) is a global public health problem. CVD patients are at high risk of recurrent stroke and other atherothrombotic events. Prevalence of risk factors, comorbidities, utilization of secondary prevention therapies and adherence to guidelines all influence the recurrent event rate. We assessed these factors in 18,992 CVD patients within a worldwide registry of stable outpatients. METHODS: The Reduction of Atherothrombosis for Continued Health Registry recruited >68,000 outpatients (44 countries). The subjects were mainly recruited by general practitioners (44%) and internists (29%) if they had symptomatic CVD, coronary artery disease, peripheral arterial disease (PAD) and/or >or=3 atherothrombotic risk factors. RESULTS: The 18,992 CVD patients suffered a stroke (53.7%), transient ischemic attack (TIA) (27.7%) or both (18.5%); 40% had symptomatic atherothrombotic disease in >or=1 additional vascular beds: 36% coronary artery disease; 10% PAD and 6% both. The prevalence of risk factors at baseline was higher in the TIA subgroup than in the stroke group: treated hypertension (83.5/82.0%; p = 0.02), body mass index >or=30 (26.7/20.8%; p < 0.0001), hypercholesterolemia (65.1/52.1%; p < 0.0001), atrial fibrillation (14.7/11.9%; p < 0.0001) and carotid artery disease (42.3/29.7%; p < 0.0001). CVD patients received antiplatelet agents (81.7%), oral anticoagulants (17.3%), lipid-lowering agents (61.2%) and antihypertensives (87.9%), but guideline treatment targets were frequently not achieved (54.5% had elevated blood pressure at baseline, while 4.5% had untreated diabetes). CONCLUSIONS: A high percentage of CVD patients have additional atherothrombotic disease manifestations. The risk profile puts CVD patients, especially the TIA subgroup, at high risk for future atherothrombotic events. Undertreatment is common worldwide and adherence to guidelines needs to be enforced. (c) 2008 S. Karger AG, Basel.
BACKGROUND:Cerebrovascular disease (CVD) is a global public health problem. CVD patients are at high risk of recurrent stroke and other atherothrombotic events. Prevalence of risk factors, comorbidities, utilization of secondary prevention therapies and adherence to guidelines all influence the recurrent event rate. We assessed these factors in 18,992 CVD patients within a worldwide registry of stable outpatients. METHODS: The Reduction of Atherothrombosis for Continued Health Registry recruited >68,000 outpatients (44 countries). The subjects were mainly recruited by general practitioners (44%) and internists (29%) if they had symptomatic CVD, coronary artery disease, peripheral arterial disease (PAD) and/or >or=3 atherothrombotic risk factors. RESULTS: The 18,992 CVD patients suffered a stroke (53.7%), transient ischemic attack (TIA) (27.7%) or both (18.5%); 40% had symptomatic atherothrombotic disease in >or=1 additional vascular beds: 36% coronary artery disease; 10% PAD and 6% both. The prevalence of risk factors at baseline was higher in the TIA subgroup than in the stroke group: treated hypertension (83.5/82.0%; p = 0.02), body mass index >or=30 (26.7/20.8%; p < 0.0001), hypercholesterolemia (65.1/52.1%; p < 0.0001), atrial fibrillation (14.7/11.9%; p < 0.0001) and carotid artery disease (42.3/29.7%; p < 0.0001). CVD patients received antiplatelet agents (81.7%), oral anticoagulants (17.3%), lipid-lowering agents (61.2%) and antihypertensives (87.9%), but guideline treatment targets were frequently not achieved (54.5% had elevated blood pressure at baseline, while 4.5% had untreated diabetes). CONCLUSIONS: A high percentage of CVD patients have additional atherothrombotic disease manifestations. The risk profile puts CVD patients, especially the TIA subgroup, at high risk for future atherothrombotic events. Undertreatment is common worldwide and adherence to guidelines needs to be enforced. (c) 2008 S. Karger AG, Basel.
Authors: U Laufs; U C Hoppe; S Rosenkranz; P Kirchhof; M Böhm; H-C Diener; M Endres; M Grond; W Hacke; T Meinertz; E B Ringelstein; J Röther; M Dichgans Journal: Nervenarzt Date: 2010-04 Impact factor: 1.214
Authors: S Goto; Y Ikeda; J C N Chan; P W F Wilson; T Cheng Yeo; C S Liau; M T Abola; G Salette; P G Steg; D L Bhatt Journal: Heart Asia Date: 2011-01-01
Authors: Ulrich Laufs; Uta C Hoppe; Stephan Rosenkranz; Paulus Kirchhof; Michael Böhm; Hans-Christoph Diener; Matthias Endres; Martin Grond; Werner Hacke; Thomas Meinertz; E Bernd Ringelstein; Joachim Röther; Martin Dichgans Journal: Clin Res Cardiol Date: 2010-08-03 Impact factor: 5.460
Authors: Yeon Suk Jung; Jung Hwa Park; Hyunha Kim; So Young Kim; Ji Young Hwang; Ki Whan Hong; Sun Sik Bae; Byung Tae Choi; Sae-Won Lee; Hwa Kyoung Shin Journal: Acta Pharmacol Sin Date: 2016-06-27 Impact factor: 6.150
Authors: J Barlinn; K Barlinn; U Helbig; T Siepmann; L-P Pallesen; H Urban; V Pütz; J Schmitt; H Reichmann; U Bodechtel Journal: Nervenarzt Date: 2016-08 Impact factor: 1.214
Authors: Stefanie Leistner; Georg Michelson; Inga Laumeier; Michael Ahmadi; Maureen Smyth; Gabriele Nieweler; Wolfram Doehner; Jan Sobesky; Jochen B Fiebach; Peter Marx; Otto Busse; Friedrich Köhler; Holger Poppert; Martin L J Wimmer; Thomas Knoll; Paul Von Weitzel-Mudersbach; Heinrich J Audebert Journal: BMC Neurol Date: 2013-01-24 Impact factor: 2.474
Authors: Stefanie Leistner; Steffen Benik; Inga Laumeier; Annerose Ziegler; Gabriele Nieweler; Christian H Nolte; Peter U Heuschmann; Heinrich J Audebert Journal: PLoS One Date: 2012-12-17 Impact factor: 3.240